Mipomersen Sodium Patent Expiration
Mipomersen Sodium is Used for reducing cholesterol levels in patients with homozygous familial hypercholesterolemia. It was first introduced by Kastle Therapeutics Llc
Mipomersen Sodium Patents
Given below is the list of patents protecting Mipomersen Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kynamro | US7511131 | Antisense modulation of apolipoprotein B expression | Jan 29, 2027 | Kastle Theraps Llc |
| Kynamro | US7101993 | Oligonucleotides containing 2′-O-modified purines |
Sep 05, 2023
(Expired) | Kastle Theraps Llc |
| Kynamro | US7015315 | Gapped oligonucleotides |
Mar 21, 2023
(Expired) | Kastle Theraps Llc |
| Kynamro | US7407943 | Antisense modulation of apolipoprotein B expression |
Aug 01, 2021
(Expired) | Kastle Theraps Llc |
| Kynamro | US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec 26, 2017
(Expired) | Kastle Theraps Llc |
| Kynamro | US6451991 | Sugar-modified gapped oligonucleotides |
Feb 11, 2017
(Expired) | Kastle Theraps Llc |
| Kynamro | US5914396 | 2'-O-modified nucleosides and phosphoramidites |
Jun 22, 2016
(Expired) | Kastle Theraps Llc |
| Kynamro | US6222025 | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
Mar 06, 2015
(Expired) | Kastle Theraps Llc |
Mipomersen Sodium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List